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Abstract
Long-term estrogen deficiency increases the risk of obesity, diabetes and metabolic syndrome in postmenopausal women.
Menopausal hormone therapy containing estrogens might prevent these conditions, but its prolonged use increases the
risk of breast cancer, as wells as endometrial cancer if used without progestins. Animal studies indicate that beneficial
effects of estrogens in adipose tissue and adverse effects on mammary gland and uterus are mediated by estrogen receptor
alpha (ERa). One strategy to improve the safety of estrogens to prevent/treat obesity, diabetes and metabolic syndrome is
to develop estrogens that act as agonists in adipose tissue, but not in mammary gland and uterus. We considered plant
extracts, which have been the source of many pharmaceuticals, as a source of tissue selective estrogens. Extracts from two
plants, Glycyrrhiza uralensis (RG) and Pueraria montana var. lobata (RP) bound to ERa, activated ERa responsive reporters,
and reversed weight gain and fat accumulation comparable to estradiol in ovariectomized obese mice maintained on a high
fat diet. Unlike estradiol, RG and RP did not induce proliferative effects on mammary gland and uterus. Gene expression
profiling demonstrated that RG and RP induced estradiol-like regulation of genes in abdominal fat, but not in mammary
gland and uterus. The compounds in extracts from RG and RP might constitute a new class of tissue selective estrogens to
reverse weight gain, fat accumulation and metabolic syndrome in postmenopausal women.
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Introduction
Menopause is associated with a profound drop in levels of
estrogens in women. This leads to estrogen deficiency which initiates
early symptoms including hot flashes, mood swings and vaginal
dryness, and contributes to long-term conditions such as osteopo-
rosis,andpossiblyother chronicconditions, including cardiovascular
disease, obesity, type 2 diabetes, metabolic syndrome and Alzhei-
mer’s disease. Postmenopausal women are frequently treated with
menopausal hormone therapy (MHT) containing estrogens that are
very effective at preventing hot flashes, urogenital atrophy and
osteoporosis [1]. The Women’s Health Initiative (WHI) trial [2,3],
Heart and Estrogen/Progestin Replacement Study [4] and Nurses’
Health Study [5] also found that MHT decreases the risk for type 2
diabetes. Other studies indicate that MHT decreases weight gain
[6,7] and prevents redistribution of fat to the abdominal cavity [8,9].
Despite these important benefits the WHI demonstrated that MHT
increases the risk of breast cancer, blood clots and cardiovascular
disease [1,10]. While controversial, the potential l adverse effects of
estrogenshave led to a large decline inMHT use[11] and anintense
pursuit to develop safer estrogens in MHT for long-term therapy.
Estrogens in MHT were introduced many years prior to the
elucidation of factors involved in estrogen receptor signaling.
Major discoveries include the identification of two estrogen
receptor subtypes, multiple classes of DNA regulatory elements
that estrogen receptors bind to in genes, and numerous
coregulator proteins and transcription factors that interact with
ERs to alter chromatin structure to regulate gene transcription
[12]. These exciting discoveries might make it possible to develop
estrogen mimetics that are more selective and do not require the
addition of progestins, which exacerbate adverse effects of
estrogens on breast cells [13].
The major problem with current estrogens used in MHT is that
they are agonists in all tissues and are therefore non-selective [14].
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4,49,40-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol (PPT) is a
highly selective ERa agonist [15]. Multiple synthetic ERb-selective
agonists have also been developed [16] with diarylpropionitrile
(DPN) and ERB-041 being the most studied [17,18]. ERb-
selective agonists have been discovered from plants, including
MF101 and liquiritigenin [19,20]. ERb-selective compounds are a
very attractive alternative to non-selective estrogens currently in
MHT because of the anti-proliferative and anti-tumor properties
of ERb [21–24], and the finding that MF101 produced a
significant reduction in hot flashes and night sweats [25].
However, there is significant data demonstrating that ERa
mediates the beneficial metabolic effects of estrogens in adipose
tissues [26,27]. Estradiol (E2) has powerful antidiabetic (with
improved insulin sensitivity and glucose tolerance) and weight-
lowering effects in ovariectomized mice and rats, and in several
rodent models of spontaneous type 2 diabetes [28,29]. ERa
knockout (ERKO) mice have increased weight gain, greater
adipose tissue, insulin resistance and impaired glucose tolerance
[30,31]. The selective ERa agonist, PPT reduced weight gain and
fat accumulation in normal mice [32,33] and improved glucose
tolerance and insulin sensitivity in obese mice [34]. In contrast, no
increase in weight is observed in ERb knockout (BERKO) mice
and the ERb agonist, DPN does not alter total body weight gain in
rats [35]. Although it is conceivable that the role of ERa and ERb
might differ in humans, the rodent studies indicate that the
beneficial effects of estrogens on fat metabolism are likely mediated
by ERa, rather than ERb.
One strategy to exploit the beneficial metabolic effects of ERa is
to identify tissue selective ERa drugs that act as agonists in adipose
tissue, but not in the mammary gland (MG) or uterus. Massive
efforts have been directed at identifying estrogens with greater
selectivity. These have employed large scale high throughput
screenings, X-ray crystallographic approaches and other methods.
Besides non-selective estrogens the only other class of estrogenic
drugs available for menopausal women are the selective estrogen
receptor modulators (SERMs), such as raloxifene that possess
mixed agonist/antagonist activity [36]. Many plants contain
phytoestrogens which, like estradiol, transactivate estrogen recep-
tors. Some phytoestrogens exhibit selectivity for ER subtypes [37].
We therefore searched for compounds in plants that have yielded
many pharmaceuticals and are popular among women [38] to
discover estrogens that might exhibit tissue specific effects which
could prevent metabolic complications during menopause. Here
we report the discovery of plant extracts that have estrogenic
activity and reverse weight gain and fat accumulation without
eliciting untoward effects on mammary gland or uterus in mice.
Materials and Methods
Plant extracts
Preparation of RG. Five kilograms of ground, dried roots of
Glycyrrhiza uralensis Fischer or Glycyrrhiza glabra L.; (Fabaceae) was
extracted twice with 25 liters of 8:2 ethanol—water for 8 h and
overnight at room temperature with constant stirring. The extract
was suction filtered through Whatman #4 filter paper, and the
combined filtrates were concentrated under reduced pressure at
50uC to approximately 2 liters to remove the ethanol. The
aqueous fraction was freeze dried to produce a stable powder that
could be diluted to a specified concentration for testing.
Preparation of RP. Five kilograms of ground, dried roots of
Pueraria montana (Lour.) Merr. var. lobata (Willd.) Maesen & S.
Almeida (Fabaceae) was extracted twice with 25 liters of 8:2
ethanol—water for 8 h and overnight at room temperature with
constant stirring. The extract was suction filtered through
Whatman #4 filter paper, and the combined filtrates were
concentrated under reduced pressure at 50uC to approximately
2 liters to remove the ethanol. Water was added to increase the
volume to 4 liters, and the aqueous fraction was partitioned four
times with an equal volume (4 L) of ethyl acetate. The ethyl
acetate layers were combined and concentrated to dryness under
reduced pressure. The remaining solids were resuspended from
the round bottom flask with a combination of water and ethanol,
and the solution was freeze dried to produce a stable powder that
could be diluted to a specified concentration for testing.
Cell culture, transfection, and luciferase assays
Human U2OS osteosarcoma, MCF-7 breast cancer and ECC-1
endometrial cancer cell lines were obtained from the American
Type Culture Collection (Manassas, VA). U2OS cells expressing a
doxycycline-inducible ERa cDNA were previously described [39].
All cell lines were maintained and subcultured as previously
described [40]. Transfections were carried out with a Bio-Rad
gene pulser as previously described [40]. Briefly, U2OS cells were
electroporated with 3 mg of ERE and NKG2E tk-Luciferase (tk-
Luc) reporter vector and 1 mg of an expression vector for ERa.
ECC-1 cells were electroporated with 3 mg of ERE tk-Luc. After
electroporation, the cells were plated and treated with E2, RG, or
RP for 18 h. Cells were then solubilized and luciferase activity was
determined with an assay kit (Promega, Madison, WI). Experi-
ments were performed at least three times and the mean 6 S.E.M.
was calculated.
ERa binding assay
Binding to ERa was determined using fluorescence polariza-
tion-based ER competitor assays per the manufacturer’s protocol
(Invitrogen, Carlsbad, CA). The 2X Fluormone
TM ES2/ERa
complex was added to a dilution series of RG and RP to generate
competition curves. The polarization was plotted against the
concentration of RG and RP. The concentration of RG and RP
that results in a half maximum shift in polarization equals the
IC50.
Xenograft studies in nude mice
MCF-7 cells were grown in DMEM/F-12 medium containing
4% stripped fetal bovine serum and re-suspended in sterile
PBS:Matrigel (1:1). MCF7 cells (250,000 cells) were injected into
the mammary fat pad (MG #4; both sides) of 8 week old CD-1
nude mice (Charles River, Wilmington, MA). The mice were
randomly separated in ten groups. Control mice were treated with
vehicle. E2 treated mice received a subcutaneous mini-pump
(Alzet, Cupertino, CA) containing 0.25 mg E2. Eight groups were
treated orally, daily, five times a week for 4 weeks with 40, 80, 160
or 320 mg/day RG or RP separately. The tumor size was
measured after 4 weeks. All animal protocols were approved by
the Institutional Animal Care and Use Committee of Bionovo. All
animal experiments were carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health.
Weight studies in mice
Twenty 10 week old, ovariectomized C57Bl/6 female mice
(Jackson Laboratory, Bar Harbor, ME) were fed with a high fat
diet (Research Diets, Inc., New Brunswick, NJ) ad libidum for 7
weeks to increase body weight. After gaining weight, the mice were
randomly separated in four groups of five mice. Two groups were
treated orally, five times a week for 6 weeks with 80 mg RG or RP
Tissue-Selective Effects of Plant Estrogens
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a continuous infusion using osmotic Alzet pumps containing
vehicle. E2 treated mice received pumps containing 0.25 mg E2 in
vehicle. Body weight was recorded weekly. At the end of the
experiment, #4 mammary glands were collected and weighed.
One gland of each pair was prepared for whole mounts and the
other one for histology and RNA extraction. The abdominal fat
depots were also collected, weighed and extracted for RNA.
Finally, the uterus was collected and weighed, and used for RNA
extraction. The experiment was reproduced and gave similar
results. The data presented are representative of both experiments.
Mammary gland whole mounts
Mammary gland whole mounts were prepared as described
previously [41]. Briefly, #4 mammary glands were dissected away
from subcutaneous tissues and fixed in freshly prepared Metha-
corn solution (60% methanol, 30% chloroform, and 10% acetic
acid) for 48 h, dehydrated, skimmed with acetone for 48 h,
rehydrated, and stained with iron hematoxylin for 2 h before
washing and Histo-Clear conservation (National Diagnostics,
Somerville, NJ) as described [41]. The mammary gland whole
mounts were examined by light microscopy to evaluate the
mammary structures.
Microarrays
Abdominal fat, #4 mammary glands and uterus tissues from the
mice described above were collected in RNAlater RNA Stabili-
zation Reagent (Qiagen). Total RNA was isolated with the Aurum
total RNA fatty and fibrous tissue kit (Bio-Rad, Hercules, CA) per
the manufacturer’s protocol. RNA was first quantified by standard
spectrophotometry, and then qualitatively evaluated by capillary
electrophoresis employing the Experion system (Bio-Rad, Hercu-
les, CA). Biotin-labeled cRNA samples were prepared with 400 ng
of total RNA template. Following synthesis and purification, the
biotin-labeled samples were evaluated by both 260/280 absor-
bance spectrophotometry and capillary electrophoresis. The final
labeled cRNA samples were hybridized overnight against
MouseWG-6 BeadChip arrays containing more than 45,200
probes (Illumina) by the University of California, San Francisco
Genomics Core.
The raw intensities data was converted into text files by Illumina
BeadStudio software package and then analyzed using the
BioConductor limma package. In particular, the data was
background corrected by Normal+Exponential model using
negative controls and then quantile normalized. A linear model
was fit by limma and p-values were computed based on moderated
t-test and adjusted for multiple testing by applying Benjamini-
Hochberg correction. Genes with adjusted p-values,0.05 were
considered statistically significant. All microarray data will be
deposited in a publicly available database.
Real-time RT-PCR
Total RNA extracted from tissues was reverse transcribed using
the iScript cDNA Synthesis Kit (Bio-Rad, Hercules, CA). Real-
time quantitative PCR was performed using SYBR Green
Supermix with an iCycler thermal cycler (Bio-Rad) as previously
described [42]. Experiments were performed at least three times.
The following PCR primers were used:
MUP1 Forward 59-CCCAGAGAGTATATAAGGACAAG-
CAAAGG-39; Reverse 59-AGTATGCCATTCCCCATTAATC-
TTTTCTAC-39; GPX3 Forward 59-GTGAGCGCGATGGC-
CGTGTA-39; Reverse 59-ACCACAGACGGGCTCAGGGG-39;
LCN2 Forward 59-TGGGGTCCTGCAGAGCCAGG-39; Re-
verse 59-CCTGCCCCGGAACTGATCGC-39; CD8B Forward
59-ACTTCTGCGCGACGGTTGGG-39; Reverse 59-GGGTG-
GGGGAACGGGCATTG-39; CD79B Forward 59-GGAGACA-
AGCTGCAGCCCAGG-39; Reverse 59-CAACAGCCAGTGG-
CAGGGCA-39; LEP Forward 59-GAGCACAAGGAGGGGC-
CAGC-39; Reverse 59-CGCAGCGAAGCGTGTACCCA-39.
Results
Plant extracts activate transcription through ERa
Eighteen plant extracts (PEs) used historically for treating
menopausal-related conditions [43] were screened for ERa
activity by transfecting U2OS cells with the classic estrogen
responsive element (ERE) upstream of the minimal thymidine
kinase promoter linked to the luciferase reporter gene (ERE tk-
Luc) and an expression vector for human ERa. Based on these
screens we selected PEs from Radix Glycyrrhiza uralensis (RG) and
Radix Pueraria montana var. lobata (RP) for further studies because
they exhibited ERa-mediated activation of ERE tk-Luc.
In addition to the classic ERE, ERa activity of RG and RP was
examined using a more complex ERa responsive regulatory
element derived from the NKG2E promoter, which requires a
collaboration between c-jun, heat-shock factor 2, and CCAAT/
enhancer-binding protein beta and a variant ERE for full
activation by E2 [44]. RG and RP were less active than E2 in
U2OS osteosarcoma cells transfected with an expression vector for
ERa [39], but they produced a significant activation of ERE
(Fig. 1A) and NKG2E (Fig. 1B) tk-Luc reporters. These data
demonstrate that RG and RP have ERa activity with different
types of estrogen response elements.
RG and RP act differently than SERMs
To investigate if RG and RP behave similarly to mixed agonist/
antagonist estrogens like the SERMs, raloxifene and tamoxifen, we
examined their effects on ERE tk-Luc in the absence and presence
of E2 in human ECC-1 endometrial cancer cells that express
endogenous ERa [45]. RG and RP produced a dose-dependent
activation of ERE tk-Luc. The activation was first observed at
1 mg/ml, and a 5–6 fold maximal activation occurred at 25 mg/ml
(Figure 1C). Raloxifene and tamoxifen did not activate ERE tk-
Luc in ECC-1 cells (Figure 1D), but raloxifene antagonized the
activation by E2, RG and RP and tamoxifen antagonized the
activation by RG and RP. Unlike the SERMs, RG and RP did not
antagonize E2 activation of ERE tk-Luc (Figure 1D). At higher
doses, RG, RP and E2 produced an equivalent activation of the
ERE in ECC-1 cells. Thus, RG and RP act exclusively as agonists,
whereas the raloxifene and tamoxifen act as an antagonist on the
ERE in these cells.
RG and RP bind to ERa
We tested RG and RP binding to ERa by fluorescence
polarization-based ER competitor assays. Both RG and RP
effectively competed with fluorescent E2 for binding to purified
full-length ERa [EC50s were 16 mg/ml and 5.5 mg/ml for RG
and RP, respectively (Figure 1E and F)]. These results demonstrate
that compounds in RG and RP bind to ERa.
ERa is required for RG and RP regulation of genes in
U2OS cells
Effects of RG and RP on endogenous genes were examined in
human U2OS cells stably transfected with doxycycline-inducible
expression for ERa. We previously demonstrated that E2
regulated numerous genes in these cells [46]. In the absence of
doxycycline ERa is not expressed [39] and only 5 genes were
regulated by RG and 33 by RP (Table 1). In contrast, after
Tissue-Selective Effects of Plant Estrogens
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regulated 1,598 genes in U2OS-ERa cells (Supplemental Table 1).
The reporter assays, competitive binding study and gene
expression data indicate that ERa mediates the effects of RG
and RP.
RG and RP reverse weight gain in high fat diet fed mice
We examined if RG and RP reverses weight gain and fat
accumulation using a high fat diet (HFD) fed mouse model. Ten
week old ovariectomized C57Bl/6 female mice were fed a HFD
for 50 days to increase body weight and abdominal fat. Once the
mice gained weight they were randomly divided into four groups
that received: (Group 1) only a HFD (control mice); (Group 2)
both E2 and HFD (positive control); (Group 3) HFD and RG
orally for 49 days; and (Group 4) HFD and RP orally, 49 days.
The total length of the study was 109 days. From day 50 to 109 the
control mice continued to gain additional 8% of body weight
(Fig. 2A). In contrast, E2 treated mice started to lose weight
significantly after one week, and continued to lose weight for the
duration of the experiment (217% at day 49 of treatment;
P,0.05, t-test). A significant weight loss was first observed after 14
days treatment with RP and 21 days with RG. Both groups
continued to lose weight during the 49 days of treatment (P,0.05,
t-test). At the end of study the mice treated with RG and RP lost
14% and 18%, respectively, from their pre-treatment body weight
at day 0, which was similar to mice treated with E2 (Fig. 2A). RG
and RP also produced a significant reduction in the weight of
gonadal, retroperitoneal, mesenchymal and omental fat depots
with a similar magnitude to E2 (Fig. 2B). RG and RP mice had a
feeding behavior similar to the control mice (Supplemental Table
Figure 1. RG and RP activate transcription through ERa. Human U2OS osteosarcoma cells were transfected with (A) ERE tk-Luc or (B) NKG2E
tk-Luc reporter vectors and an expression vector for ERa. After transfection, the cells were treated for 18 h with 10 nM E2, 10 mg/ml RG or 10 mg/ml
RP and luciferase activity was measured. (C) ECC-1 cells were transfected with ERE tk-Luc and treated with increasing amounts of RG and RP for
18 hours and then luciferase activity was measured. (D) ECC-1 cells were transfected with ERE tk-Luc and treated with 1 nM E2, 1 mM raloxifene, 1 mM
tamoxifen, 25 mg/ml RG or 25 mg/ml RP individually or in combination for 18 hours and then luciferase activity was measured. Each data point is the
average of triplicate samples 6 S.E.M. (E) RG and (F) RP binding to purified ERa was assayed by fluorescence polarization-based ER competitor assays.
Serial dilutions of RG and RP were tested and the IC50 determined. * represents a significant difference from control (P,0.05, t-test).
doi:10.1371/journal.pone.0028333.g001
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food intake.
RG and RP do not mimic E2 on mammary gland and
uterus
Potential proliferative effects of RG and RP on the MG were
assessed by examining their morphology in whole mounts after 49
days of treatment. E2 increased the number of branching ductal
structures compared to control mice (Figs. 3A). The MGs of RG-
and RP-treated mice had a similar phenotype to control mice with
few ductal structures indicating that they did not stimulate
epithelial cell proliferation and differentiation (Fig. 3A). Uterine
size (Fig. 3B) and weights (Fig. 3C) in the RG- and RP-treated
groups were similar to the control mice, whereas E2 produced a
marked increase in uterine size and weight. These data
demonstrate that unlike E2, RG and RP exert favorable tissue-
specific effects that reverse body weight and fat accumulation
without causing proliferative effects on the MG and uterus.
Unlike E2, RG and RP gene regulation is adipose tissue
specific
To examine if RG and RP produce tissue specific effects at the
genomic level, we compared gene expression profiles in gonadal
fat, MG and uterus in response to E2, RG and RP. In gonadal fat,
E2, RG and RP each regulated over 1,000 genes (Table 2). The
genes regulated are listed in Supplemental Table 2. 24% of genes
regulated by RG and RP overlapped with genes regulated with E2
indicating that RG and RP can regulate the activity of ER in
adipose tissue. In contrast, RG and RP regulated 0 or 22 genes,
respectively in the MG compared to 479 genes regulated by E2.
The lack of effects on gene regulation by RG and RP is consistent
with the absence of proliferation in the MG observed in whole
mounts after treatment. In the uterus E2 regulated 2239 genes,
whereas RG regulated 229 genes and RP regulated 664 genes
(Supplemental Table 3). The overall profile of gene regulation
clearly demonstrates the tissue specificity of RG and RP.
Some genes regulated by E2, RG and RP in adipose tissue have
been implicated in obesity and were verified by real time PCR.
Table 1. RG and RP regulate many genes only when U2OS
cells express ERa.
Treatment Number of genes regulated
2dox RG vs. 2dox Control 5
2dox RP vs. 2dox Control 33
+dox RG vs. +dox Control 347
+dox RP vs. +dox Control 1598
U2OS cells stably transfected with a doxycycline-inducible ERa were maintained
for 24 h in the absence of doxycycline (2dox) or presence of 1 mg/ml
doxycycline (+dox). The cells were then treated without (Control) or with RG or
RP for 18 h. The number of genes regulated was defined by a statistically
significant (p,0.05) 2-fold or greater activation or a repression greater than
50%. The microarrays were done in triplicate.
doi:10.1371/journal.pone.0028333.t001
Figure 2. RG and RP reverse weight gain and fat accumulation in mice fed a high fat diet. Ten week old ovariectomized C57Bl/6 female
mice were placed on a HFD for 50 days to increase body weight and abdominal fat. After 50 days on a HFD the mice gained about 40% in body
weight and then they were treated orally for 7 weeks with 80 mg/day RG or RP while being maintained on a HFD. E2 treated mice received a
subcutaneous pump containing E2. Each mouse was weighed weekly. (A) Percentage of weight change at the duration of treatment to the initial
body weight at day 0 when the drugs were started (50 days on HFD). Each data are expressed as average 6 S.E.M. (P,0.05, t-test). * represents
significant differences after treatment to day 0 weight (P,0.05, t-test). (B) The weights of the gonadal, retroperitoneal, mesenchymal and omental fat
depots were measured for each mouse. The data represent the average weight per treatment in each mouse (n=56S.E.M.). * represents significant
differences in treated mice compared to control mice (P,0.05, t-test).
doi:10.1371/journal.pone.0028333.g002
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peroxidase 3 (GPX3) (Fig. 4A) genes were up-regulated by all three
treatments. The lipocalin 2 (LCN2) gene was up-regulated by E2,
but not by RG and RP (Fig. 4C). Expression of CD8B (Fig. 4D)
and CD79B (Fig. 4E) antigens were down-regulated by all three
treatments. The leptin (LEP) gene was down-regulated by E2, but
not by RG and RP (Fig. 4F).
RG and RP do not promote estrogen-dependent MCF-7
breast cancer tumor growth
We analyzed potential estrogenic effects of RG and RP in a
human cell system using the estrogen dependent MCF-7 breast
cancer xenograft model. Eight week old ovariectomized nude
female mice were implanted with MCF-7 cells in the mammary fat
pad. The mice were randomly divided into ten groups. The first
group received vehicle (control mice) and the second group
received E2 using a mini-osmotic pump. The other groups were
treated orally for 4 weeks with 40, 80, 160 or 320 mg/day of RG
or RP separately. The E2 treated mice developed tumor nodules
in every MG pad that were always large enough to be measured in
three dimensions (Fig. 5; P,0.05, t-test). In mice treated with of
RG and RP the tumors typically did not develop, but when they
did they were minimal in size and not different from controls at all
doses tested. Thus, RG and RP do not have estrogenic activity in
human MCF-7 cell xenograft model.
Discussion
The current studies illustrate the issue with E2 acting in a non-
tissue selective manner leading to both beneficial and adverse
effects as observed in clinical trials with MHT [1]. Our study
demonstrates the non-tissue selective effect of E2 by showing that
it had agonist activity in mouse adipose tissue, MG and uterus. To
overcome this non-selective agonist action, we identified RG and
RP plant extracts, and demonstrated that they exhibit tissue
selective estrogenic activity. RG and RP had the same favorable
agonist activity as E2 on metabolic parameters, which was
demonstrated by a reversal of weight gain and fat accumulation.
These beneficial effects were previously shown to be mediated by
ERa in mice [30]. However, RG and RP did not promote other
known actions mediated by ERa, such as the proliferation of
mouse MG cells, increasing uterine growth or stimulating MCF-7
breast cancer tumor formation in a mouse xenograft model. These
Figure 3. RG and RP do not mimic estradiol in mammary gland and uterus. The mammary glands and uterus were collected from the mice
used to study body weight and fat weight (Figure 2) at the end of the 7 weeks of treatment. Eight week old mature mice were ovariectomized. At 10
weeks of age, mice were fed a high fat diet for 7 weeks and then treatment with E2, RG and RP was started. The high fat diet was continued during
treatment. After 7 weeks of treatment the same animals were used for body weight, fat weight, mammary gland and uterus study. (A) Representative
mammary gland whole mounts are shown. (B) Representative pictures of the uterus are shown. (C) The weights of uterus were measured for each
mouse. The data represent the average weight per treatment (n=5 mice6S.E.M), normalized to the average weight of control mice * represents
significant differences compared to estradiol treated mice (P,0.05, t-test).
doi:10.1371/journal.pone.0028333.g003
Table 2. RG and RP gene regulation profile mimics estradiol in fat only.
Tissue Treatment Induced genes Repressed genes Total genes regulated Common E2 % of E2
Gonadal Fat E2 662 517 1179
Gonadal Fat RG 270 768 1038 287 24.34
Gonadal Fat RP 332 724 1046 284 24.09
Mammary Gland E2 208 271 479
Mammary Gland RG 0 0 0 0 0
Mammary Gland RP 18 4 22 10 2.09
Uterus E2 1250 989 2239
Uterus RG 6 223 229 92 4.11
Uterus RP 259 405 664 248 11.08
Gene expression from gonadal fat, mammary gland and uterus was analyzed by microarray. The number of genes induced and repressed by estradiol (E2), RG and RP
and the total number of gene regulated per tissue are specified compared to control mice. The number of genes regulated by RG and RP that are commonly regulated
by E2 are shown (common E2) and specified as a percentage of E2 regulated genes (% of E2).
doi:10.1371/journal.pone.0028333.t002
Tissue-Selective Effects of Plant Estrogens
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adipose tissue, while not producing ERa agonist effects on mouse
MG and uterus, and human MCF-7 cell xenografts.
The non-selective tissue agonist action of E2 was also
demonstrated at a genomic level using microarrays as E2 regulated
1,179 genes in adipose tissue, 2,239 genes in the uterus and 479
genes in the MG. In contrast, RG and RP regulated genes in a
tissue-specific manner. RG and RP regulated a similar number of
genes in adipose tissue as E2, but much fewer genes in MG and
uterus. The overlap of regulated genes between E2 and RG or RP
was also much greater in adipose tissue compared to MG and
uterus. 24% of genes regulated by RG and RP in adipose tissue
overlapped with those regulated by E2, whereas there was only 0–
2% overlap in the MG and a 4–11% overlap in the uterus. It is
likely that different genes regulated by RG and RP compared to
E2 account for their tissue selective agonist actions. These findings
demonstrate that RG and RP mimic the effects of E2 on gene
expression more strongly in adipose tissue than the MG and
uterus.
The mechanisms whereby RG and RP exert tissue-specific
effects are unknown. One possibility is selective tissue uptake of the
compounds. For example, an active ER-binding compound in
these extracts is diffused or transported to the fat but not to the
MG or uterus. Another possibility is that RG and RP might
activate ERa in the adipose tissue and not in the mammary gland
or uterus where it is known to promote proliferation. This could
occur if RG and RP binding to ERa causes a recruitment of tissue-
specific coregulators or transcription factors required for regulat-
ing gene transcription. For example, the coactivator NCOA1 is
highly expressed in endometrial cancer cells, but is present in low
levels in breast cancer cells. The higher expression of NCOA1
allows tamoxifen to act as an ERa agonist in endometrial cancer,
but not in breast cancer cells [47]. Northern blot analysis showed
distinct tissue-specific expression patterns of coregulatory genes
[48]. There is also tissue-specific expression of coregulator proteins
in reproductive organs [49]. These findings suggest a major
determinant of the tissue-specific response to estrogens is the
expression of different coregulator proteins in tissues. Another
possibility is that some other chemicals in the extracts block ERa
action in MG and uterus, but not in the adipose tissue. These
issues will require further study.
Our microarray analysis of adipose tissue identified several
genes commonly regulated by E2, RG and RP that might be
involved in mediating the reversal of weight gain and fat
accumulation. GPX3 might be an important mediator of estrogen
effects in relation to fat accumulation because GPX3 levels are
Figure 4. RG and RP effects on expression of genes selected from microarrays. Relative mRNA levels for (A) MUP, (B) GPX3, (C) LCN2, (D)
CD8B, (E) CD79B and (F) LEP in gonadal fat tissue from control (C), E2, RG and RP treated mice as determined by real-time PCR normalized to b-actin.
Each data point is the average of four samples 6 S.E.M. * represents a significant difference from control (P,0.05).
doi:10.1371/journal.pone.0028333.g004
Figure 5. RG and RP do not stimulate tumor growth of MCF-7
cells in xenografts. Eight week old nude mice were injected with
MCF-7 cells in the mammary fat pad of both MG #4. The mice were
treated with vehicle control (C), 0.25 mg E2 per pump or RG and RP at
40, 80, 160 and 320 mg daily. The data represent the average tumor
size per treatment 6 S.E.M. for measurable tumors. * represents
significant differences in treated mice compared to control mice
(P,0.05, t-test).
doi:10.1371/journal.pone.0028333.g005
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genes regulated by E2, RG and RP that also may be important in
mediating the anti-obesity effects encode for the major urinary
proteins (MUPs), which regulate systemic glucose and lipid
metabolism through paracrine/autocrine regulation of liver
metabolic activity [50].
Since RG and RP are crude extracts it is possible that their
effects on weight gain, fat accumulation and gene regulation are
produced by compounds that affect other cellular pathways, rather
than ER signaling. A lack of an effect on ERa could explain why
RG and RP do not cause proliferation in the mammary gland and
uterus. It is conceivable that some of the effects of RG and RP
were mediated through ERb because ERb agonists do not
stimulate the mammary gland and uterus and the ERb agonist,
MF101, produced a modest, but statistically significant reduction
in both weight and body mass index in postmenopausal women,
compared to placebo after 12 weeks of treatment [25].
Furthermore, we observed that RG and RP can activate ERb in
transfection assays (data not shown). However, it is unlikely that
effects of RG and RP on weight and fat accumulation are
mediated through ERb. First, mouse adipose tissue expressed
mainly ERa. Second, the in vivo gene expression profiling analysis
shows that RG and RP and E2 regulate approximately 1000 genes
in fat tissue, whereas in the mammary gland tissue RG and RP
regulated 0 and 22 genes, respectively even though it expresses
ERb [51]. The lack of genes regulated in the MG indicates that
RG and RP do not regulate ERa or ERb in the mammary gland.
Third, RG and RP regulated 229 and 664 genes, respectively in
the mouse uterus which expresses very little ERb [52] indicating
that these genes were likely regulated by ERa. However, it is
possible that ERb-selective drugs may exert beneficial effect on
obesity and metabolism indirectly through regulation of other
tissues and not through direct effects on adipocytes. It is also
possible that the effects of RG and RP are mediated by a pathway
that does not involve ERs, but this seems unlikely because no
genes were regulated in U2OS cells that did not express ERa,
whereas many genes were regulated by RG and RP when ERa
was present. Although crude plant extracts were used in these
studies it is clear that RG and RP show promising tissue selective
agonist activity, and are worthy of further investigation to
characterize the pure active compounds and verify that the effects
of RG and RP on adipose tissue are mediated by ERa. Our
findings demonstrate that the plant extracts have estrogenic
activity and reverse weight gain and fat accumulation without
stimulating the proliferation of the mouse mammary gland and
uterus. RG, RP and their active compounds might constitute a
new class of tissue selective estrogen agonists to prevent previous
indications for MHT requiring long-term use, such as osteoporo-
sis, as well as new indications, such as obesity, type 2 diabetes, and
metabolic syndrome.
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